CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 6328 result(s)

dupilumab (Dupixent)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: dupilumab
Indications: Dupixent is indicated as an add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.

  • Brand Name: Dupixent
  • Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
  • Project Number: SR0667-000
  • Project Status: Active
  • Submission Type: Initial

fremanezumab (Ajovy)

Last Updated: December 18, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: fremanezumab
Indications: ​Indicated for the prevention of migraine in adults who have at least 4 migraine days per month.

  • Brand Name: Ajovy
  • Manufacturer: Teva Canada Innovation
  • Project Number: SR0641-000
  • Project Status: Active
  • Submission Type: Initial

semaglutide (Rybelsus)

Last Updated: December 24, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: semaglutide
Indications: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; in combination with other medicinal products for the treatment of diabetes

  • Brand Name: Rybelsus
  • Manufacturer: Novo Nordisk Canada Inc.
  • Project Number: SR0637-000
  • Project Status: Active
  • Submission Type: Initial

azacitidine (Onureg)

Last Updated: March 2, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: azacitidine
Indications: ​Maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT).

  • Brand Name: Onureg
  • Manufacturer: Celgene Inc., a Bristol-Myers Squibb Company
  • Project Number: PC0245-000
  • Project Status: Received
  • Submission Type: Initial

Venetoclax (Venclexta)

Last Updated: March 3, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: venetoclax
Indications: Venclexta is indicated, in combination with a hypomethylating agent or in combination with low-dose cytarabine, in adult patients with newly diagnosed acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.

  • Brand Name: Venclexta
  • Manufacturer: AbbVie Corporation
  • Project Number: PC0238-000
  • Project Status: Active
  • Submission Type: Initial

venetoclax (Venclexta)

Last Updated: March 3, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: venetoclax
Indications: In combination with azacitidine or low-dose cytarabine is indicated for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

  • Brand Name: Venclexta
  • Manufacturer: AbbVie Corporation
  • Project Number: PC0239-000
  • Project Status: Active
  • Submission Type: Initial

larotrectinib (Vitrakvi)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: larotrectinib
Indications: For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.

  • Brand Name: Vitrakvi
  • Manufacturer: Bayer Inc.
  • Project Number: PC0221-000
  • Project Status: Active
  • Submission Type: Resubmission